Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 27;6(1):e000819.
doi: 10.1136/bmjophth-2021-000819. eCollection 2021.

Adalimumab in patients with vision-threatening uveitis: real-world clinical experience

Timothy Lee Tang Lee Say #  1   2 , Verlyn Yang #  3   4   5 , Jacob M Fingret  1 , Sophia Zagora  1   6   7 , Richard Symes  1   7 , Christine Younan  1   7 , Elisa Eleanor Cornish  1   7 , Nitin Verma  3   5   8 , Anthony Sammel  1   9 , Denis Wakefield  6   9 , Deborah Speden  3 , Peter J McCluskey  1   3   6   7
Affiliations

Adalimumab in patients with vision-threatening uveitis: real-world clinical experience

Timothy Lee Tang Lee Say et al. BMJ Open Ophthalmol. .

Abstract

Objectives: Biologics are rapidly emerging as an effective vision saving addition to systemic uveitis therapy. The aim of this multicentre retrospective study is to review the outcomes of a large group of patients treated with adalimumab.

Methods: A retrospective chart review of patients with refractory non-infectious, active uveitis treated with adalimumab was conducted. The main outcome measures were ability to reduce prednisolone dose, ability to control uveitis, final visual acuity and time to treatment failure.

Results: Forty-six patients with uveitis, treated with adalimumab were included in the study. The most common anatomical uveitis phenotype was panuveitis (n=17, 37.0%). The most common diagnosis was idiopathic uveitis (n=19, 41.3%). At their latest review (mean: 4.46 years; median 4.40 years), 35 (76.1%) patients were able to discontinue corticosteroids, 11 (23.9%) patients were able to taper to <7.5 mg/day and only 1 (2.2%) patient required 10 mg of prednisone. The mean visual acuity at the latest follow-up of the worse eye was logarithm of the minimum angle of resolution (logMAR) 0.42 (SD 0.72), while the mean visual acuity of the better eye was logMAR 0.19 (SD 0.34). Of the 89 eyes, 21 (23.6%) eyes improved by at least 2 lines, 5 eyes (5.6%) deteriorated by ≥2 lines while vision was unchanged in the remaining 63 (70.8%) eyes. The time to recurrence was 1 in 12.47 person-years for adalimumab, with a 17.4% (8 patient) relapse rate. There were no serious adverse events.

Conclusions: This study highlights the efficacy of adalimumab in patients with vision-threatening non-infectious uveitis, preserving vision and allowing reduction of corticosteroid dose.

Keywords: drugs; immunology; inflammation; vision.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Kaplan-Meier plot of the rate and time to treatment failure of patients on adalimumab.
Figure 2
Figure 2
Reasons for adalimumab initiation.
Figure 3
Figure 3
Prednisone dose in patients on adalimumab and/or concurrent conventional immunosuppressive agents.
See this image and copyright information in PMC

References

    1. Jabs DA. Immunosuppression for the Uveitides. Ophthalmology 2018;125:193–202. 10.1016/j.ophtha.2017.08.007 - DOI - PMC - PubMed
    1. Wakefield D, Dunlop IAN, McCLUSKEY PJ, et al. . Uveitis: aetiology and disease associations in an Australian population. Aust N Z J Ophthalmol 1986;14:181–7. 10.1111/j.1442-9071.1986.tb00034.x - DOI - PubMed
    1. Trusko B, Thorne J, Jabs D, et al. . The standardization of uveitis Nomenclature (sun) project. development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med 2013;52:259–65. 10.3414/ME12-01-0063 - DOI - PMC - PubMed
    1. Zagora SL, Symes R, Yeung A, et al. . Etiology and clinical features of ocular inflammatory diseases in a tertiary referral centre in Sydney, Australia. Ocul Immunol Inflamm 2017;25:sup1:S107–14. 10.1080/09273948.2016.1247871 - DOI - PubMed
    1. Haroon M, O'Rourke M, Ramasamy P, et al. . A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the duet (Dublin uveitis evaluation tool). Ann Rheum Dis 2015;74:1990–5. 10.1136/annrheumdis-2014-205358 - DOI - PubMed

LinkOut - more resources